PB

Purple Biotech

PPBT
TEL AVIV STOCK EXCHANGEHealth Care
$1.64
USD
-0.05(-2.96%)
At close: Jun 16, 20:00 UTC

Open

$1.68

Prev. Close

$1.68

High

$1.68

Low

$1.68

Market Snapshot

Market Cap

$3.05M

P/E Ratio

0.1

EPS

-8022.00

Employees

10

About

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 10 full-time employees. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Recently from Cashu